This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The United Nations COP26 climate talks are scheduled for October 31 to November 12 in Glasgow, Scotland. Heads of state will be joined by private sector leaders to once again discuss the shrinking window of time left to take action against global temperature rise. Barbara Humpton, CEO of focused technology company Siemens U.S., is also attending and spoke to Cheddar about what she hopes to see during the conference for both the public and private spheres. "What we are really urging is that there are large commitments made in Glasgow and that we really commit to this next decade of action," she said.
Voyager, Nanoracks, and Lockheed Martin are all teaming up to develop the first-ever free-flying commercial space station with room for a crew of four astronauts. The private companies are joining forces as part of NASA’s greater mission to retire the International Space Station by the year 2030. The low-earth orbit space station will be called "Starlab," and is planned to achieve operational capability by 2027. Lisa Callahan, Vice President and General Manager of Commercial Civil Space at Lockheed Martin, and Matthew J. Kuta, President and Chief Operating Officer of Voyager Space, joined Cheddar’s Opening Bell.
Jill and Carlo cover the latest developments in the Alec Baldwin prop gun shooting, when vaccines for kids as young as 5 should be approved, new reporting on Facebook and more.
Middle school students from across the country battled it out for a chance at being crowned 'America's Top Scientist.' Each applicant had to submit a video to compete in the '3M Young Scientist Challenge' and describe a unique solution to an everyday problem for the chance to win $25,000. 10 finalists were chosen and after a two-day virtual competition, one walked away with the title. 14-year-old Sarah Park won the award, she joins Cheddar News to talk about her invention Spark Care+.
NIAID Director Dr. Anthony Fauci has stated that recipients of the single-dose Johnson & Johnson COVID-19 vaccine should have gotten two doses, to begin with. An FDA panel had recently recommended that J&J boosters be made available for everyone who received the single dose.
Richard Branson’s Virgin Galactic is delaying its launch date for commercial space flights to Q4 of 2022 following a rescheduled test flight. Shares for the aerospace company fell on the news.
The NIH released findings of a study that say recipients of the Johnson & Johnson COVID-19 vaccine may benefit from getting Pfizer or Moderna boosters as the antibody levels from those shots were seen as more robust than from a Johnson & Johnson booster.
"Star Trek" actor William Shatner's voice broke with emotion as he recounted his trip into space on the Blue Origin New Shepard rocket to Jeff Bezos on October 13, 2021.
